

**Quality Compliance Form**

| <b>Osteoporosis Management in Women (OMW)</b>                                 |  |           |
|---|--|-----------|
| <b>Provider Information</b>   |  |           |
| Provider Name   |  |           |
| Address   |  |           |
| Specialty   |  |           |
| NPI   |  |           |
| Tax ID  |  |           |
| Contact Name  |  |           |
| Contact Phone   |  |           |
| <b>Patient Information</b>  |  |           |
| Patient Name  |  |           |
| DOB   |  |           |
| Highmark Blue Shield of Northeastern New York Insurance                       | Primary  | Secondary |
| ID#   |  |           |
| Measure/Description   | This intervention targets women 67-85 years of age (1938-1956) who suffered a fracture and who had a bone mineral density test (BMD) ordered to treat osteoporosis in the six months after the fracture occurring July 1, 2022 through June 30, 2023.  |           |
| <b>Required Documents</b><br><br>*CCD's are not accepted per NCQA regulations | Documentation of appropriate testing or treatment for osteoporosis. This documentation includes: <ul style="list-style-type: none"> <li>• A BMD test in any setting, or</li> <li>• Osteoporosis therapy (osteoporosis medication) or, if an inpatient stay, long-acting osteoporosis therapy during the inpatient stay. (Evidence that the member is receiving medication samples during 2023. <b>NDC Code must be included</b>).</li> </ul> |           |
| Comments  |  |           |

Highmark Blue Shield of Northeastern New York is a trade name of Highmark Western and Northeastern New York Inc., an independent licensee of the Blue Cross Blue Shield Association.